Close Menu
The Business TimesThe Business Times
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
What's On

Children as young as 13 'with ketamine bladder', says new research

22 September 2026

Sonoco Products: Dividend Aristocrat Value In Plain Sight (NYSE:SON)

22 September 2026

Arm Holdings: The Narrative Can’t Justify The Current Share Price (NASDAQ:ARM)

22 September 2026

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

22 September 2026

PGIM Quant Solutions International Equity Fund Q2 2026 Commentary

22 September 2026
Facebook X (Twitter) Instagram
Business Tuesday, Sep 22
The Business TimesThe Business Times
Newsletter
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
The Business TimesThe Business Times
Home » Team, Inc. (TISI) Q2 2026 Earnings Call Transcript
News

Team, Inc. (TISI) Q2 2026 Earnings Call Transcript

thebusinesstimes.co.ukBy thebusinesstimes.co.uk11 August 20262 Views
Facebook Twitter LinkedIn Reddit Telegram WhatsApp Pinterest Tumblr VKontakte Email
Share
Facebook Twitter LinkedIn Pinterest Email

Operator

Welcome to the Team, Inc. Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Joseph Caminiti with Alpha IR Group. Please go ahead.

Joe Caminiti
Alpha IR Group LLC

Thank you, operator. Good morning, everyone, and welcome to Team, Inc.’s Second Quarter 2026 Earnings Call. Joining me on today’s call are Gary Hill, Team’s Chief Executive Officer; and Clinton Roeder, Team’s Chief Financial Officer.

Before we begin, I would like to remind everyone that management’s remarks today may contain forward-looking statements, including statements regarding revenue, gross margin, operating expenses, adjusted EBITDA, cash flow and the company’s future business outlook. These statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Risk Factors section of Team’s most recent annual and quarterly reports filed with the Securities and Exchange Commission as well as the company’s second quarter earnings release. Team undertakes no obligation to update any forward-looking statements, which speak as of their respective dates.

With that, I will turn the call over to Gary Hill, Team’s Chief Executive Officer.

Gary Hill
Chief Executive Officer

Good morning, everyone, and thank you for joining us. I’ll begin with a brief overview of the second quarter, then spend most of my time discussing what I’ve learned during my first roughly 120 days as CEO and the actions we are taking to position Team for stronger and more

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp

Related Articles

Children as young as 13 'with ketamine bladder', says new research

Sonoco Products: Dividend Aristocrat Value In Plain Sight (NYSE:SON)

Arm Holdings: The Narrative Can’t Justify The Current Share Price (NASDAQ:ARM)

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

PGIM Quant Solutions International Equity Fund Q2 2026 Commentary

Pain of NHS whistleblowers as call for Lucy Letby retrial grows louder

Wealthfront Is Good Value As Further Rate Hikes Loom (NASDAQ:WLTH)

Your Lunch Today Proves What The Fed Can’t Really Fix (NYSEARCA:SPY)

BrainsWay: Execution Isn’t The Problem, Market Size Is (NASDAQ:BWAY)

Editors Picks

Sonoco Products: Dividend Aristocrat Value In Plain Sight (NYSE:SON)

22 September 2026

Arm Holdings: The Narrative Can’t Justify The Current Share Price (NASDAQ:ARM)

22 September 2026

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

22 September 2026

PGIM Quant Solutions International Equity Fund Q2 2026 Commentary

22 September 2026

Subscribe to News

Get the latest finance and business news and updates directly to your inbox.

Latest Posts

Pain of NHS whistleblowers as call for Lucy Letby retrial grows louder

22 September 2026

Wealthfront Is Good Value As Further Rate Hikes Loom (NASDAQ:WLTH)

22 September 2026

Your Lunch Today Proves What The Fed Can’t Really Fix (NYSEARCA:SPY)

22 September 2026
Facebook X (Twitter) Pinterest WhatsApp TikTok Instagram
© 2026 The Business Times. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.